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Background: The aim was to investigate, whether 5,000 IUaXa/day certoparin lowers the incidence of deep vein
thrombosis (DVT) in patients undergoing elective hip replacement surgery vs. 3,000 IUaXa/day. Double-blind,
multicenter, randomised trial in 500 patients. Primary endpoint: incidence of symptomatic or asymptomatic DVT
(bilateral ascending venography).
Results: Mean age was 71 ± 10 years with a higher prevalence of previous DVT (8vs.4%) and pulmonary embolism
(PE) (4vs.1%) in the high dose group. Mean duration of surgery was 82 ± 32 and 85 ± 36 min. DVT was detected in
28 (11.1%) of the low dose and 35 (14.1%) of the high dose group (p = n.s.). Combined distal-proximal DVT was
observed in 5 (2%) and 4 (1.6%) patients respectively. No difference in bleeding events was found.
Conclusion: This trial confirms prior data showing that the conventional dosage of 3,000 IU aXa is effective and
safe for the prevention of venous thromboembolic events after hip replacement surgery.Background
Venous thromboembolism (VTE) is, without appropriate
prophylaxis, a frequent complication in patients undergo-
ing hip replacement with an incidence of 60% [1,2]. Even
with pharmacological and physical prophylaxis there is a
rate of 10-20% for asymptomatic distal, 5-10% for asymp-
tomatic proximal, 2–5% of symptomatic thrombosis and
of 0.3% for pulmonary embolism [3].
Against this background patients undergoing hip re-
placement surgery are a high risk group in itself and fur-
ther stratification according to age, co-morbidity and
other risk factors is not mandated. To cope with this risk
current guidelines on the prevention of venous
thromboembolism recommend to prefer low molecular
weight heparin (LMWH) or Fondaparinux over unfrac-
tionated heparin (UFH) for peri- and postoperative
prophylaxis [3]. Since the various LMWHs differ in re-
gard to molecular weight and pharmacological proper-
ties different treatment regimes and doses may be* Correspondence: peter.bramlage@ippmed.de
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reproduction in any medium, provided the orrecommended. Certoparin is one of these LMWHs that
is currently registered for preventing VTE in high risk
patients (including orthopaedic surgery), patients at
medium risk (including general surgery), and after ische-
mic insult, as well as medical patients with acute illness
of various origin at a fixed body-weight independent
dose of 3,000 IE aXa/d. Certoparin was shown to be ef-
ficacious and safe in surgical and non-surgical patients
[4-9]. According to a meta-analysis on the dosing of
various other LMWH it was however shown, that there
is a strong correlation between LMWH dosage and the
risk of DVT (p = 0.03) [10].
In a prior randomized, controlled trial by Adolf et al.
[8] in 341 patients undergoing hip replacement, the rate
of deep vein thrombosis, detected by bilateral ascending
venography, was not different in the 3,000 IE aXa/d
(n = 17, 9.9%) and the 5,000 IE aXa/d group (n = 16,
9.5%). Bleeding complications were also not significantly
different between groups, except for cell saver volumes
(p< 0.001). We aimed to confirm these data in a further
randomized, controlled trial, comparing the efficacy and
safety of standard certoparin prophylaxis (3,000 UI aXa/
d) to high dose certoparin prophylaxis (5,000 IU aXa/d)
in patients with elective hip replacement.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.








Duration (min) 81.9 ± 31.5 84.5 ± 36.0
Type*
Cemented 212 (86%) 198 (85%)
Not-cemented 32 (13%) 28 (12%)
Hybrid (cem. stem, not-cem cup) 1 (0.4%) 4 (2%)
Others 2 (0.8%) 2 (0.8%)
Type of anaesthesia
Duration (min 99.7 ± 34.3 102.8 ± 41.1
General anaesthesia 143 (57.9%) 129 (55.6%)
Epidural/spinal anaesthesia 40 (16%) 37 (15.9)
General + epidural/spinal anaesth. 58 (24%) 71 (7%)
*Values refer to number of patients; n.a., not available.
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Patient characteristics
A total number of 500 patients were enrolled into the
trial. 252 patients were allocated to 3,000 IU aXa/d Cer-
toparin (low dose group) and 248 to 5,000 IU aXa/d
Certoparin (high dose group). Baseline characteristics of
the patients are summarized in Table 1. They had a
mean age of 70.6 ± 9.6 (low dose) and 71.7 ± 10.6 (high
dose) years. Approximately one third of the patients
were male (36.9% vs. 33.1%; respectively). Most frequent
predisposing risk factors in both groups were varices
(35.7% vs. 35.1%), leg edema (27.0% vs. 35.1%) and previ-
ous hip surgery (30.2% vs. 33.9%). No relevant differ-
ences were found between the two groups except in the
previous rate of DVT (p = 0.047) and previous pulmon-
ary embolism (p = 0.011) with significantly higher inci-
dence rates in the high dose certoparin group.
Surgical intervention
Cemented hip prosthesis was the most predominant type
of hip replacement (212 vs. 198 for Certoparin 3,000 IU
aXa/d and Certoparin IU 5,000 aXa/d; respectively), fol-
lowed by non-cemented hip replacement (32 vs. 28)
(Table 2). The mean duration of the surgery was
81.9± 31.5 min in the low-dose group and 84.5± 36.0 min
in the high dose group. No relevant differences were
found between groups concerning duration and type of
surgery and anaesthesia techniques.Incidence of thromboembolic events
The incidence rates of thromboembolic events are






Age (years) mean± SD 70.6 ± 9.6 71.7 ± 10.6 n.s.
Sex (male) 93 (37%) 82 (33%) n.s
Weight (kg) mean± SD 71.3 ± 15.3 71.4 ± 14.9 n.s
Predisposing risk factor
Smoker 43 (17%) 41 (17%) n.s.
Previous hip surgery 76 84 n.s.
Previous DVT 9 (4%) 19 (8%) 0.047
Previous pulmonary embolism 2 (1%) 11 (4%) 0.011
Obesity 46 (19%) 58 (23%) n.s.
Hypertension 57 (23%) 71 (29%) n.s.
Frequent bleeding episodes 2 (0.8%) 0 (0.0%) n.s.
Leg edema 68 87 n.s.
Varices 90 (36%) 87 (35%) n.s.
Varicous ulcer 12 (4.8%) 18 (7.3%) n.s.
DVT, deep venous thrombosis; SD, standard deviation: n.s., not significants.group and 43 in the high-dose group refused venog-
raphy, did not receive venography for medical reasons
or were withdrawn from the study for other reasons.
Deep vein thrombosis (DVT) was diagnosed by venog-
raphy in 28 (11.1%) patients receiving low dose and in
35 (14.1%) patients receiving high dose certoparin. Com-
bined distal-proximal DVT was observed in five patients
(2.0%) receiving 3,000 IU aXa/d and in four (1.6%) re-
ceiving 5,000 IU aXa/d. Differences between dosing
groups were statistically non-significant. There were two
cases of suspected pulmonary embolism in the low dose
and none in the high dose group (p = 0.16), which were
based on a clinical diagnosis only.Bleeding complications
Peri-operative bleedings occurred in 105 patients of the
low dose group and in 120 patients of the high doseFigure 1 Incidence of thromboembolic events: DVT, deep
venous thrombosis.
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related were observed in the high dose group compared
to the low dose group (p = 0.01; Table 3). In contrast the
low dose group required significantly more transfusions,
packed cells, fresh frozen plasmas and had higher blood
losses (p< 0.001). No differences between the groups
were found regarding postoperative bleeding parameters
(Table 3).Laboratory parameters
aPTT, HEPTEST and platelet counts were performed
pre-operatively and post-operatively at day 1, 5 and last
postoperative day. No significant aPPT prolongation was
found for either low or high dose group, no significant
difference in the number of platelet drop downs
<100.000/μl was detected. HEPTEST values at day 5
were 0.21 ± 0.12 IU/ml under 3,000 IU and 0.28 ± 0.18













Transfusions 98 118 n.s.
whole blood
(ml; mean± SD)
885 ± 297 1033± 505 <0.001
Packed cells
(ml; mean± SD)
700 ± 392 504± 253 <0.001
Fresh frozen plasma
(ml; mean± SD)
617 ± 165 480± 234 <0.001
Drain loss
(ml; mean± SD)
333 ± 241 361± 266 n.s.
Other blood loss
(ml; mean± SD)
467 ± 250 225± 75 <0.001
Wound hematoma 4 1 n.s.
Wound oozing 130 128 n.s.
Wound revision 0 1 n.s.
Postoperative bleeding parameters*












Other reoperations 5 4 n.s.
*Values refer to number of patients.The results for the coagulation parameters aPTT,
HEPTEST and platelets are shown in Table 4. aPTT
values of both groups were not significantly different,
whereas HEPTEST values were significantly higher
under 5,000 IU aXa/d. Platelet count beyond 100,000/μl
was more often in the high-dose group, but without
being statistically significant.Adverse events
During the course of the study two patients of each group
died. In the low-dose group one patient died due to
massive gastrointestinal bleeding and another due to myo-
cardial infarction. In the high dose group two patients
died due to coronary insufficiency resp. myocardial infarc-
tion. Table 5 summarizes the serious adverse events. Dif-
ferences between treatment groups were non-significant.Discussion
The present study confirms prior randomized, controlled
trial data that 5,000 IU aXa/d certoparin are no more ef-
fective than 3,000 IU aXa/d in preventing thrombo-
embolic events in patients undergoing elective hip
replacement. It also confirms that bleeding complications
are nominally increased in the high-dose group. There-
fore current dosing patterns recommending 3,000 IU
aXa/d for the prevention of venous thromboembolism in









Preoperatively 42.5 ± 13.1 42.3 ± 12.0 n.s.
Post-op day 1 49.2 ± 17.1 51.9 ± 18.5 n.s.
Post-op day 5 43.9 ± 10.9 45.5 ± 14.3 n.s.
Last post-op day 44.7 ± 19.6 45.0 ± 19.7 n.s.
HEPTEST (IU/ml; mean±SD)
Preoperatively 0.16 ± 0.18 0.21 ± 0.29 0.021
Post-op day 1 0.27 ± 0.16 0.33 ± 0.17 <0.001
Post-op day 5 0.21 ± 0.12 0.28 ± 0.18 <0.001
Last post-op day 0.21 ± 0.12 0.29 ± 0.18 <0.001
Number of platelet counts<100,000/μl
Preoperatively 0 1 n.s.
Post-op day 1 1 6 n.s.
Post-op day 5 3 0 n.s.
Last post-op day 1 1 n.s.
*Values refer to number of patients; ** (ml; mean ± SD).
Table 5 Incidence of SAE’s according to
EC-GCP-guidelines






Wound hematoma 2 5
Wound hematoma infection - -
Wound infection - -
Bleeding events 3 9
Non-Bleeding-related SAE
Chest pain 1 1
Myocardial infarction 1 2
AV-Block 0 1
Pulmonary embolism 0 1
Staphylococcus aureus infection 3 0
Metastatic carcinoma - -
Coxarthrosis - -
Prostata-adenoma - -
Retention of urine - -
Implant dislocation 2 3
Implant change 0 1
Second hip surgery 3 0
Further fracture 0 1
Any other re-operation 0 1
SAE, Serious Adverse Event; all differences are statistically not significant.
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For patients undergoing elective total hip replacement
(THR), the recent ACCP guidelines recommend the rou-
tine use of one of the following anticoagulant options
[11]: LMWH, fondaparinux, apixaban, dabigatran, rivar-
oxaban, low-dose unfractionated heparin (LDUH),
adjusted-dose VKA, aspirin (all Grade 1B), or an inter-
mittent pneumatic compression device (IPCD) (Grade
1 C). The recommendation for LMWH is based on a
number of large trials [12-16] that have reported all
DVT rates of about 13.7%, proximal DVT of 3.4% and
pooloed rates of major bleeding in 5.3% of patients.
The present DVT rates are in agreement with the
aforementioned rates reported for LMWH (13.7%) and
confirm prior results published by Adolf et al. in 342
patients with elective hip replacement [8]. In the Adolf
trial [8], comparing also standard (3,000 IU aXa/d) and
high dose (5,000 IU aXa/d) certoparin, the rates of DVT
were nominally lower (standard dose: 9.9% vs. high dose:
9.5%) than in our study (11.1% vs. 14.1%, respectively).
The higher incidence of DVT in the high-dose certo-
parin group in our study may be explained by the signifi-
cantly higher portion of patients with previous DVT andPE (Table 1). Incidence rates were also comparable to
another certoparin study comparing 3,000 IU aXa/d as a
fixed-dose combination with dihydroergotamin 0.5 mg
(DHE), evaluated against dose adjusted unfractionated
heparin (UFH) subcutaneously every 8 hours. DVT was
detected in 12.0% in the LMWH/DHE group, no pul-
monary embolism was detected [17].
Certoparin at a dose of 3,000 aXa/d IU is registered
for VTE prophylaxis in surgical and non-surgical
patients. This registration is based on trials comparing
different doses and dosing regimens between 3,000,
5,000 IU certoparin and other comparators [4,5,8,17].
They all demonstrated non-inferiority of 3,000 IU aXa/d
certoparin versus the chosen comparator. Repetitive
administrations of 3,000 IU antiXa certoparin after 12 or
24 hours led to no cumulation.
The study also confirms that rates of bleeding compli-
cations are similar for both dosing groups although
heparin-related bleeding was more frequent in the high-
dose group. This also fits with the data provided by
Adolf et al [8]. We further confirmed the observation of
the trial by Adolf et al., that in the high dose group more
whole blood transfusions were given but less cell saver
and FFP volumes compared to the low dose group.
Results are difficult to compare however to rates of
major bleedings reported for LMWH (5.3%) because of
different definitions used.
Limitations
The present data have been acquired in the late 1990’s
and clinical treatment pathways and techniques for
(elective) hip replacement have changed since then. This
is a major limitation of the present trial which was
planned and conducted at times when the composite
endpoint of VTE related death, deep venous thrombosis
and pulmonary embolism was not yet defined as the
generally accepted primary endpoint of such studies.
The same limitation has to be considered for the safety
endpoint, which nowadays includes predefined major
and minor bleeding events, that can´t be easily com-
pared to the present bleeding criteria, which are men-
tioned in Table 3. Further, while the main study
outcome was assessed by an independent radiologist,
unaware of the dosis assignment no independent adjudi-
cation committee was employed. We are convinced
however that the current data should be published, to
make them accessible to the scientific community for
transparency purposes.
Conclusions
This clinical trial confirms available data on maximal
antithrombotic efficacy and an excellent safety profile of
3,000 versus 5,000 IU aXa/d certoparin in the prevention
of thromboembolic events after elective hip replacement.
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complications after major orthopaedic surgery when low
molecular weight heparins are used for prophylaxis.
Methods
This study was a double-blind, multicenter, prospective,
randomised trial. It was approved by an independent
ethics committee and performed according to the Dec-
laration of Helsinki. Prior to enrolment patients` written
informed consent was obtained.
Patients
Patients aged at least 40 years and of either gender
scheduled for elective primary hip replacement were eli-
gible for inclusion. Exclusion criteria were severe renal
impairment (serum creatinine> 200 μmol/l) or hepatic
dysfunction (INR> 1.2), severe hypertension (BP> 200/
105 mmHg), known bleeding diathesis, allergy to hep-
arin or its fragments, allergy to iodine containing radio-
opaque contrast media, hyperthyroidism, premenopausal
women being pregnant or not actively preventing preg-
nancy, breast feeding and participation in a clinical trial
four weeks prior to inclusion in this trial as well as usage
of drugs which might influence coagulation within seven
days prior to surgery.
Treatment allocation
After inclusion patients were randomly allocated to one of
two treatment groups receiving subcutaneously either
3,000 or 5,000 IU aXa of certoparin once a day. The injec-
tions were applied in the morning at least two hours prior
to surgery. The prophylactic treatment was continued for
a minimum of 8 up to a maximum 16 days.
Endpoint definition
The efficacy endpoint was the incidence of asymptom-
atic or symptomatic proximal or distal DVT. Bilateral
venography was performed between the 8th and the 16th
postoperative day in all asymptomatic patients. In
patients with clinical signs suggesting DVT, bilateral
ascending venography was performed immediately after
the symptoms were recognised (early venography).
Venographies were blinded and examined by an inde-
pendent expert radiologist according to clinical routine
standard procedures. Clinical signs of pulmonary embol-
ism (PE) were to be verified by pulmonary scintigraphy.
Bleeding events and other safety parameters
For safety, adverse events especially bleeding complica-
tions were observed. Intraoperative blood loss was
assessed by the surgeons. In addition the blood loss from
drains in the whole postoperative prophylaxis period
was documented. Surgical wounds were examined
daily for hematomas and wound oozing. All intra- andpostoperative transfusions, bleeding related discontinua-
tions and reoperations as well as all serious or non-
serious adverse events, observed during the prophylactic
treatment, were documented. HEPTEST, aPTT, and
thrombocyte count were determined preoperatively, on
the first and the fifth postoperative day as well as on the
day of discharge. There was no screening for thrombo-
cyte directed antibodies however.
Statistics
The sample size calculation was made on the basis of
available literature at the time of study conception. VTE
incidence after hip surgery was estimated occurring des-
pite prophylaxis in about 30%. An assumed decrease of
that rate of about 10% was estimated for the high dose
group. A sample size of 500 patients was calculated in-
cluding planned drop outs to achieve a power of 90% at
a significance level of 0.05. The incidence of thrombo-
embolic events were calculated on the basis of an intent-
to-treat analysis. Statistical testing was performed with
the unpaired t-test or with the uncorrected Chi-square
test.
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